<i>In vivo</i>evaluation of the antifungal activity of sertraline against<i>Aspergillus fumigatus</i>

Treviño-Rangel, Rogelio de J.; Villanueva-Lozano, Hiram; Méndez-Galomo, Karen S; Solís-Villegas, Elia M; Becerril-García, Miguel A.; Montoya, Alexandra M.; Robledo-Leal, Efrén; González, Gloria M.

doi:10.1093/jac/dky455

Cited by 22 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[32,33,[45][46][47][48][49][50][51], Aspergillus spp. [13,29,35,[52][53][54][55][56][57][58][59][60][61], Mucorales [62][63][64], Madurella mycetomatis [65][66][67], and other fungal agents [68][69][70]. The contribution of G. mellonella to the evaluation of antifungal drugs will be detailed in the following paragraphs.…”

Section: Evaluation Of Antifungal Efficacy In Galleria Mellonellamentioning

confidence: 99%

“…The treatment of G. mellonella infected with Aspergillus spp. has been evaluated in several studies (Table 4) in order to assess intrinsic resistance in specific species [55,56,83], acquired azole resistance in A. fumigatus [53,54], combinations [35,59], and efficacy of non-antifungal drugs [29,57,58,60,61]. A. fumigatus VRZ (10) AMB (3) sertraline (3,10)…”

Section: Aspergillus Sppmentioning

confidence: 99%

“…Correlation with murine model. [61] AMB: amphotericin B, VRZ: voriconazole, TBF: terbinafine, CAS: caspofungin, BMQ: bromoquinol, CANBEF-24: 4-chloro-6-arylamino-7-nitro-benzofurazane, GdA: geldanamycin, Gm: Galleria mellonella.…”

Section: Nomentioning

confidence: 99%

“…G. mellonella has also been used as an in vivo model for the evaluation of antifungal efficacy of new drugs [57,58,60] or in the context of repurposing [29,61]. By screening large chemical libraries, several drugs with promising antifungal activity were identified and further tested in animal models, including G. mellonella [57,58,60].…”

Section: Nomentioning

confidence: 99%

“…Sertraline, a selective serotonin reuptake inhibitor used as antidepressant also has antifungal activities and it has been used recently as an adjunctive therapy in cryptococcal meningitis [86]. Trevino-Rangel et al [61] compared the efficacy of sertraline for the treatment of invasive aspergillosis in G. mellonella and BALB/c male mice to the efficacy of amphotericin B and voriconazole. Outcome parameters were survival in G. mellonella and fungal burden in mice.…”

Section: Nomentioning

confidence: 99%

See 4 more Smart Citations

Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review

et al. 2020

View full text Add to dashboard Cite

The treatment of invasive fungal infections remains challenging and the emergence of new fungal pathogens as well as the development of resistance to the main antifungal drugs highlight the need for novel therapeutic strategies. Although in vitro antifungal susceptibility testing has come of age, the proper evaluation of therapeutic efficacy of current or new antifungals is dependent on the use of animal models. Mammalian models, particularly using rodents, are the cornerstone for evaluation of antifungal efficacy, but are limited by increased costs and ethical considerations. To circumvent these limitations, alternative invertebrate models, such as Galleria mellonella, have been developed. Larvae of G. mellonella have been widely used for testing virulence of fungi and more recently have proven useful for evaluation of antifungal efficacy. This model is suitable for infection by different fungal pathogens including yeasts (Candida, Cryptococcus, Trichosporon) and filamentous fungi (Aspergillus, Mucorales). Antifungal efficacy may be easily estimated by fungal burden or mortality rate in infected and treated larvae. The aim of the present review is to summarize the actual data about the use of G. mellonella for testing the in vivo efficacy of licensed antifungal drugs, new drugs, and combination therapies.

show abstract

Section: Evaluation Of Antifungal Efficacy In Galleria Mellonellamentioning

confidence: 99%

Section: Aspergillus Sppmentioning

confidence: 99%

Section: Nomentioning

confidence: 99%

Section: Nomentioning

confidence: 99%

Section: Nomentioning

confidence: 99%

See 3 more Smart Citations

Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review

et al. 2020

View full text Add to dashboard Cite

show abstract

Drug repurposing strategies in the development of potential antifungal agents

Zhang

Liu

Zeng

et al. 2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

The morbidity and mortality caused by invasive fungal infections are increasing across the globe due to developments in transplant surgery, the use of immunosuppressive agents, and the emergence of drug-resistant fungal strains, which has led to a challenge in terms of treatment due to the limitations of three classes of drugs. Hence, it is imperative to establish effective strategies to identify and design new antifungal drugs. Drug repurposing is a potential way of expanding the application of existing drugs. Recently, various existing drugs have been shown to be useful in the prevention and treatment of invasive fungi. In this review, we summarize the currently used antifungal agents. In addition, the most up-to-date information on the effectiveness of existing drugs with antifungal activity is discussed. Moreover, the antifungal mechanisms of existing drugs are highlighted. These data will provide valuable knowledge to stimulate further investigation and clinical application in this field. Key points • Conventional antifungal agents have limitations due to the occurrence of drug-resistant strains. • Non-antifungal drugs act as antifungal agents in various ways toward different targets. • Non-antifungal drugs with antifungal activity are demonstrated as effective antifungal strategies.

show abstract

Evaluation of the synergistic antifungal activity of micafungin and voriconazole plus sertraline against Candida auris

et al. 2022

View full text Add to dashboard Cite

Candida auris is an emerging global public health threat. It is an opportunistic yeast that usually affects critically ill patients in healthcare settings and is characterized by reduced susceptibility to multiple antifungal classes. Combination therapy with antifungals and repurposed drugs is a feasible alternative to overcome this problem. The aim of this study was to examine the in vitro interactions and potential synergy of micafungin (MFG) and voriconazole (VRC) plus the antidepressant sertraline (SRT) against clinical isolates of C. auris . Conventional antifungal testing was first performed with the three drugs according to the CLSI methodology. Drug interactions were determined by the checkerboard microdilution assay using the fractional inhibitory concentration (FIC) index. Synergistic interactions were noted with the combination of MFG and SRT plus VRC with FIC values of 0.37 to 0.49 for some strains. Indifferent interactions were observed when MFG was combined with SRT with just one exception (FIC 0.53). No antagonism was observed for any combination. The combination of VRC with MCF or SRT may be relevant for treating C. auris infections.

show abstract

In vivoevaluation of the antifungal activity of sertraline againstAspergillus fumigatus

Cited by 22 publications

References 17 publications

Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review

Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review

Drug repurposing strategies in the development of potential antifungal agents

Evaluation of the synergistic antifungal activity of micafungin and voriconazole plus sertraline against Candida auris

Contact Info

Product

Resources

About